Tim E. Darsaut

Tim E. Darsaut

Auto-generated profile, based on publicly available information

Tim E. Darsaut

University of Alberta Hospital

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Trials
Verified
Journal Article
Open access
PDF file
TDTim E Darsaut
Tim E Darsaut
AJAndrew S Jack
Andrew S Jack
RKRichard S Kerr
Richard S Kerr
JRJean Raymond
Jean Raymond
The International Subarachnoid Aneurysm Trial (ISAT) demonstrated improved one-year clinical outcomes for patients with ruptured intracranial aneurysms treated with endovascular coiling compared to surgical clipping. Patients included in ISAT were mostly good grade subarachnoid hemorrhage (SAH) patients with small anterior circulation aneurysms. The purported superiority of coiling is commonly extrapolated to patients not studied in the original trial or to those treated using new devices not available at the time. Conversely, many patients are treated by clipping despite ISAT, because they are thought either to be better candidates for surgery, or to offer more durable protection from aneurysm recurrences. These practices have never been formally validated. Thus, for many ruptured aneurysm patients the question of which treatment modality leads to a superior clinical outcome remains unclear.

11 May 2023 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
TDT.E. Darsaut
T.E. Darsaut
JFJay Max Findlay
Jay Max Findlay
MBM.W. Bojanowski
M.W. Bojanowski
CCC. Chalaala
C. Chalaala
DID. Iancu
D. Iancu
JRJ. Raymond
J. Raymond
BACKGROUND AND PURPOSE: Surgical clipping and endovascular treatment are commonly used in patients with unruptured intracranial aneurysms. We compared the safety and efficacy of the 2 treatments in a randomized trial. MATERIALS AND METHODS: Clipping or endovascular treatments were randomly allocated to patients with one or more 3- to 25-mm unruptured intracranial aneurysms judged treatable both ways by participating physicians. The study hypothesized that clipping would decrease the incidence of treatment failure from 13% to 4%, a composite primary outcome defined as failure of aneurysm occlusion, intracranial hemorrhage during follow-up, or residual aneurysms at 1 year, as adjudicated by a core lab. Safety outcomes included new neurologic deficits following treatment, hospitalization of >5 days, and overall morbidity and mortality (mRS > 2) at 1 year. There was no blinding. RESULTS: Two hundred ninety-one patients were enrolled from 2010 to 2020 in 7 centers. The 1-year primary outcome, ascertainable in 290/291 (99%) patients, was reached in 13/142 (9%; 95% CI, 5%–15%) patients allocated to surgery and in 28/148 (19%; 95% CI, 13%–26%) patients allocated to endovascular treatments (relative risk: 2.07; 95% CI, 1.12–3.83; P = .021). Morbidity and mortality (mRS >2) at 1 year occurred in 3/143 and 3/148 (2%; 95% CI, 1%–6%) patients allocated to surgery and endovascular treatments, respectively. Neurologic deficits (32/143, 22%; 95% CI, 16%–30% versus 19/148, 12%; 95% CI, 8%–19%; relative risk: 1.74; 95% CI, 1.04–2.92; P = .04) and hospitalizations beyond 5 days (69/143, 48%; 95% CI, 40%–56% versus 12/148, 8%; 95% CI, 5%–14%; relative risk: 0.18; 95% CI, 0.11–0.31; P < .001) were more frequent after surgery. CONCLUSIONS: Surgical clipping is more effective than endovascular treatment of unruptured intracranial aneurysms in terms of the frequency of the primary outcome of treatment failure. Results were mainly driven by angiographic results at 1 year.

4 November 2015 in Trials
Verified
Journal Article
Open access
PDF file
TDTim E. Darsaut
Tim E. Darsaut
EMElsa Magro
Elsa Magro
JGJean-Christophe Gentric
Jean-Christophe Gentric
ABAndré Lima Batista
André Lima Batista
CCChiraz Chaalala
Chiraz Chaalala
JRJean Raymond
Jean Raymond
The management of unruptured brain arteriovenous malformation (AVM) patients remains controversial. Furthermore, curative attempts to treat ruptured AVM patients have not been questioned so far, and there is a lack of prospective data on clinical results according to treatment modality. Endovascular treatment is often used aiming to improve the safety or efficacy of surgery or radiation therapy, but benefits have never been documented in a trial. A care trial context is needed to evaluate interventions at the same time they are practised. TOBAS is a pragmatic, prospective, multicenter, randomized, controlled trial and registry which offers a care trial context for brain AVM patients, including surgical resection, radiosurgery or endovascular embolization, alone or combined. The study includes two RCTs and a multimodality prospective registry. The objectives of the proposed study are to assess whether preventive interventions (surgery, embolization, radiation therapy, alone or combined), selected by the local treatment team and performed as locally practiced, randomly allocated and compared with conservative management, in unruptured brain AVM patients eligible for active or conservative management, can improve the proportion of patients having an independent outcome (modified Rankin Scale (mRS) < 3, as assessed by a standardized questionnaire administered by non-masked care personnel) at 10 years. All patients judged ineligible for randomized allocation are to be entered in a multimodal registry. The objective of a nested trial in patients with ruptured or unruptured AVMs to be treated by surgery or radiation therapy, is to assess whether pre-surgical or pre-radiation embolization, randomly allocated and compared with no embolization, can improve the proportion of patients with complete eradication of the AVM, as locally adjudicated, combined with a good clinical outcome (mRS < 3). The study will require up to 2000 patients in approximately 30 centers or more, followed for 10 years. TOBAS is registered at clinicaltrials.gov: NCT02098252 as of 25 March 2014.

1 June 2017 in Journal Of Neuroradiology
Verified
Journal Article
Closed access
NKNaim N. Khoury
Naim N. Khoury
TDTim E. Darsaut
Tim E. Darsaut
JGJimmy Ghostine
Jimmy Ghostine
YDYan Deschaintre
Yan Deschaintre
NDNicole Daneault
Nicole Daneault
JRJean Raymond
Jean Raymond

1 January 2011 in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Verified
Journal Article
Open access
PDF file
TDTim E. Darsaut
Tim E. Darsaut
JFJ. Max Findlay
J. Max Findlay
JRJean Raymond
Jean Raymond
Background: Once a decision has been made to treat an intact aneurysm, the best treatment remains uncertain. Both surgical and endovascular management strategies are commonly performed for these lesions. Surgical clipping, for years the standard treatment, is gradually becoming supplanted by endovascular treatment. However, there is no randomized data available to compare the results of surgery versus endovascular treatment of unruptured aneurysms (UIAs).Methods: We report the design of the Canadian UnRuptured Endovascular versus Surgery (CURES) trial to compare angiographic and clinical outcomes following treatment of UIAs.Results: The Canadian pilot phase will serve two purposes: i) to determine feasibility of the pivotal international study, and ii) to determine the incidence of treatment failure, a composite primary end-point comprising the occurrence of either: failure to accomplish aneurysm obliteration with the initial treatment modality, a major saccular aneurysm remnant or recurrence, or intracranial hemorrhage following treatment at one year. The pivotal international study will address which strategy leads to the best overall clinical outcomes in terms of mortality, morbidity, and clinical efficacy. CURES is designed to be a pragmatic management trial with loose inclusion criteria. The pilot study plans to enroll 260 patients, a size sufficient (at 80% power and 0.05 significance) to detect a decrease in the incidence of treatment failure from 13% to 4%. The formulation of specific hypotheses for the pivotal phase awaits the preliminary CURES morbidity and mortality results.Conclusions: The CURES trial intends to test surgical versus endovascular management strategies for the treatment of unruptured intracranial aneurysms.

1 June 2011 in Interventional Neuroradiology
Verified
Journal Article
Open access
PDF file
JRJ. Raymond
J. Raymond
TDT.E. Darsaut
T.E. Darsaut
FGF. Guilbert
F. Guilbert
AWA. Weill
A. Weill
DRD. Roy
D. Roy
Intracranial aneurysms, particularly large and giant, fusiform or recurrent aneurysms are increasingly treated with flow diverters (FDs), a recently introduced and approved neurovascular device. While some rare cases may not be treated any other way, in most patients a more conventional, conservative, or validated approach such as coiling, parent vessel occlusion, or surgical clipping exists. Only a randomized clinical trial can answer the question of which treatment option leads to better patient outcomes. We report the design of the FIAT study, a clinical care trial aiming to compare angiographic and clinical outcomes following treatment with a Flow-Diverter or with the best conventional treatment option. The FIAT study will include both a randomized and a registry portion. Patients will be proposed randomization to either FD stenting or best conventional treatment option (observation, coiling, stenting, or clipping) as determined by the treating physician. FIAT will recruit a total of 338 patients, to show that i) FD stenting can be performed with an ‘acceptable’ immediate complication rate of less than 15% morbidity and mortality (defined as mRS > 2); ii) FD stenting can increase from 75 to 90% the proportion of patients with a “good outcome”, defined as complete or near-complete occlusion of the aneurysm AND a good clinical outcome (mRS ≤ 2) at one year, as compared to the best conventional option. The FIAT study provides a scientific and ethical context to care for patients eligible for flow-diversion therapy.